Literature DB >> 24684595

The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

Lawrence D Horwitz1, Marcus A Horwitz.   

Abstract

SIGNIFICANCE: Exochelins are lipid- and water-soluble siderophores of Mycobacterium tuberculosis with unique properties that endow them with exceptional pharmacologic utility. Exochelins can be utilized as probes to decipher the role of iron in normal and pathological states, and, since they rapidly cross cell membranes and chelate intracellular iron with little or no toxicity, exochelins are potentially useful for the treatment of a number of iron-dependent pathological phenomena. RECENT ADVANCES: In animal models, exochelins have been demonstrated to have promise for the treatment of transfusion-related iron overload, restenosis after coronary artery angioplasty, cancer, and oxidative injury associated with acute myocardial infarction and transplantation. CRITICAL ISSUES: To be clinically effective, iron chelators should be able to rapidly enter cells and chelate iron at key intracellular sites. Desferri-exochelins, and other lipid-soluble chelators, can readily cross cell membranes and remove intracellular free iron; whereas deferoxamine, which is lipid insoluble, cannot do so. Clinical utility also requires that the chelators be nontoxic, which, we hypothesize, includes the capability to prevent iron from catalyzing free radical reactions which produce •OH or other reactive oxygen species. Lipid-soluble iron chelators currently available for clinical application are bidentate (deferiprone) or tridentate (desferasirox) molecules that do not block all six sites on the iron molecule capable of catalyzing free radical reactions. In contrast, desferri-exochelins are hexadentate molecules, and by forming a one-to-one binding relationship with iron, they prevent free radical reactions. FUTURE DIRECTIONS: Clinical studies are needed to assess the utility of desferri-exochelins in the treatment of iron-dependent pathological disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684595      PMCID: PMC4224048          DOI: 10.1089/ars.2013.5789

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  57 in total

1.  Desferri-Exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron.

Authors:  Yvonne K Hodges; Howard D Weinberger; Janet Stephens; Marcus A Horwitz; Lawrence D Horwitz
Journal:  Transl Res       Date:  2006-08       Impact factor: 7.012

Review 2.  Iron-mediated cardiovascular injury.

Authors:  L D Horwitz; E A Rosenthal
Journal:  Vasc Med       Date:  1999       Impact factor: 3.239

Review 3.  The evolution of iron chelators for the treatment of iron overload disease and cancer.

Authors:  Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2005-12       Impact factor: 25.468

4.  Identification of an ABC transporter required for iron acquisition and virulence in Mycobacterium tuberculosis.

Authors:  G Marcela Rodriguez; Issar Smith
Journal:  J Bacteriol       Date:  2006-01       Impact factor: 3.490

5.  Paradoxical effects of iron chelation on growth of vascular endothelial cells.

Authors:  Yvonne K Hodges; Sara M Reese; Paula M B Pahl; Lawrence D Horwitz
Journal:  J Cardiovasc Pharmacol       Date:  2005-06       Impact factor: 3.105

6.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 7.  Coordination chemistry and biology of chelators for the treatment of iron overload disorders.

Authors:  Paul V Bernhardt
Journal:  Dalton Trans       Date:  2007-07-05       Impact factor: 4.390

8.  A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells.

Authors:  Paula M B Pahl; Sara M Reese; Lawrence D Horwitz
Journal:  J Exp Ther Oncol       Date:  2007

9.  Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion.

Authors:  Dong Fu; Des R Richardson
Journal:  Blood       Date:  2007-04-11       Impact factor: 22.113

10.  Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.

Authors:  Michael A Gerber; Robert S Baltimore; Charles B Eaton; Michael Gewitz; Anne H Rowley; Stanford T Shulman; Kathryn A Taubert
Journal:  Circulation       Date:  2009-02-26       Impact factor: 29.690

View more
  3 in total

1.  Gallium Compounds Exhibit Potential as New Therapeutic Agents against Mycobacterium abscessus.

Authors:  Maher Y Abdalla; Barbara L Switzer; Christopher H Goss; Moira L Aitken; Pradeep K Singh; Bradley E Britigan
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

2.  PPE37 Is Essential for Mycobacterium tuberculosis Heme-Iron Acquisition (HIA), and a Defective PPE37 in Mycobacterium bovis BCG Prevents HIA.

Authors:  Michael V Tullius; Susana Nava; Marcus A Horwitz
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

3.  A reevaluation of iron binding by Mycobactin J.

Authors:  Courtney F McQueen; John T Groves
Journal:  J Biol Inorg Chem       Date:  2018-07-16       Impact factor: 3.358

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.